Wave Life Sciences USA, Inc.
Clinical trials sponsored by Wave Life Sciences USA, Inc., explained in plain language.
A biotech company developing RNA-based therapies for genetic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- RNA editing drug hopes to fix genetic flaw in rare lung and liver disease Results expected Sep 2026 (estimated)
-
RNA editing drug hopes to fix genetic flaw in rare lung and liver disease
Disease control OngoingThis early-phase trial tests an experimental drug called WVE-006 in 24 people with a severe form of alpha-1 antitrypsin deficiency (Pi*ZZ). The drug is designed to edit RNA to help the body produce a working version of the protective protein. The main goal is to check safety, but…
Phase 1/2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for duchenne: Long-Term drug safety trial underway
Disease control By invitation onlyThis study looks at the long-term safety of an experimental drug called WVE-N531 in people with Duchenne muscular dystrophy (DMD) who have already taken it in a previous study. About 175 participants will receive the drug and be monitored for side effects, heart and lung function…
Phase 2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC